BR112016005899A2 - composições compreendendo populações heterogêneas de proteínas de fator xa de coagulação recombinante humano - Google Patents

composições compreendendo populações heterogêneas de proteínas de fator xa de coagulação recombinante humano

Info

Publication number
BR112016005899A2
BR112016005899A2 BR112016005899A BR112016005899A BR112016005899A2 BR 112016005899 A2 BR112016005899 A2 BR 112016005899A2 BR 112016005899 A BR112016005899 A BR 112016005899A BR 112016005899 A BR112016005899 A BR 112016005899A BR 112016005899 A2 BR112016005899 A2 BR 112016005899A2
Authority
BR
Brazil
Prior art keywords
compositions
coagulation factor
proteins
human recombinant
heterogeneous populations
Prior art date
Application number
BR112016005899A
Other languages
English (en)
Other versions
BR112016005899A8 (pt
Inventor
C Rouse Jason
A Johnson Keith
Beth Switzer Mary
Anthony Jankowski Michael
Shamashkin Michael
Jane SHARPE Penelope
B Weston Stacey
Carol PIACENZA Wendy
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR112016005899A2 publication Critical patent/BR112016005899A2/pt
Publication of BR112016005899A8 publication Critical patent/BR112016005899A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Water Supply & Treatment (AREA)
  • Toxicology (AREA)

Abstract

a presente invenção refere-se a composições que compreendem vari-antes recombinantes do fator xa de coagulação humana. tais composições incluem uma ampla variedade de isoformas e modificações pós-traducionais de fxa e são úteis para tratamento de indivíduos com necessidade de hemóstase.
BR112016005899A 2013-09-24 2014-09-16 composições compreendendo populações heterogêneas de proteínas de fator xa de coagulação recombinante humano, seus usos e método de purificação de uma proteína variante de fator xa. BR112016005899A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361881834P 2013-09-24 2013-09-24
PCT/IB2014/064564 WO2015044836A1 (en) 2013-09-24 2014-09-16 Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins

Publications (2)

Publication Number Publication Date
BR112016005899A2 true BR112016005899A2 (pt) 2017-09-26
BR112016005899A8 BR112016005899A8 (pt) 2018-02-06

Family

ID=51844797

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016005899A BR112016005899A8 (pt) 2013-09-24 2014-09-16 composições compreendendo populações heterogêneas de proteínas de fator xa de coagulação recombinante humano, seus usos e método de purificação de uma proteína variante de fator xa.

Country Status (19)

Country Link
US (3) US9757434B2 (pt)
EP (1) EP3049434A1 (pt)
JP (1) JP6429885B2 (pt)
KR (1) KR101988705B1 (pt)
CN (2) CN105579468A (pt)
AR (1) AR097732A1 (pt)
AU (1) AU2014326257B2 (pt)
BR (1) BR112016005899A8 (pt)
CA (1) CA2924981C (pt)
HK (1) HK1218760A1 (pt)
IL (2) IL244258A0 (pt)
MX (1) MX2016003871A (pt)
MY (1) MY173548A (pt)
PE (1) PE20160877A1 (pt)
RU (1) RU2648144C2 (pt)
SA (1) SA516370751B1 (pt)
SG (1) SG11201601221XA (pt)
TW (1) TWI631134B (pt)
WO (1) WO2015044836A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014118677A1 (en) 2013-01-31 2014-08-07 Pfizer Inc. Compositions and methods for counteracting factor xa inhibition
MY173548A (en) 2013-09-24 2020-02-04 Pfizer Fxa variant compositions
DK3472314T3 (da) * 2016-06-17 2021-07-26 Alexion Pharma Inc Fremstilling af faktor-xa-derivater
EP3722418A1 (en) * 2019-04-08 2020-10-14 AB Enzymes Oy Solution stable enzyme composition

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597799A (en) 1990-09-04 1997-01-28 Cor Therapeutics, Inc. Recombinant agents affecting thrombosis
AT405517B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
AT405516B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
AT410216B (de) 1999-08-10 2003-03-25 Baxter Ag Faktor x-analogon mit verbesserter aktivierbarkeit
US20040102388A1 (en) 2000-03-22 2004-05-27 High Katherine A. Modified blood clotting factors and methods of use
FR2831170B1 (fr) 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
FR2841904B1 (fr) 2002-07-03 2004-08-20 Inst Nat Sante Rech Med Analogues de facteurs x clivables par la thrombine
CA2592521A1 (en) 2004-08-17 2006-02-23 Csl Behring Gmbh Modified vitamin k dependent polypeptides
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
MX336958B (es) 2005-11-15 2016-02-05 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
EP1820508A1 (en) 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
EP2915564B1 (en) * 2007-09-28 2020-11-04 Portola Pharmaceuticals, Inc. Antidotes for factor XA inhibitors and methods of using the same
KR101700722B1 (ko) 2008-06-24 2017-01-31 옥타파마 아게 응고 인자 ｖｉｉｉ을 정제하는 방법
EP2364165B1 (en) 2008-11-14 2018-01-03 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
WO2010070137A1 (en) 2008-12-19 2010-06-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Serine protease derivatives and uses in the prevention or the treatment of blood coagulation disorders
JP6163304B2 (ja) * 2009-07-15 2017-07-12 ポートラ ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子インヒビターの解毒剤の単位用量処方物およびその使用方法
SI2591006T1 (sl) * 2010-07-09 2019-10-30 Bioverativ Therapeutics Inc Enoverižne molekule, ki jih lahko obdelujemo in polipeptidi izdelani z njihovo uporabo
FR2972114B1 (fr) 2011-03-01 2013-03-15 Univ Grenoble 1 Un nouveau leurre moleculaire procoagulant pour le traitement des hemophiles a ou b avec ou sans inhibiteur
US9371522B2 (en) 2011-09-30 2016-06-21 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
NZ703148A (en) 2012-07-25 2016-08-26 Catalyst Biosciences Inc Modified factor x polypeptides and uses thereof
WO2014118677A1 (en) 2013-01-31 2014-08-07 Pfizer Inc. Compositions and methods for counteracting factor xa inhibition
MY173548A (en) 2013-09-24 2020-02-04 Pfizer Fxa variant compositions
WO2015066606A2 (en) 2013-11-01 2015-05-07 The Children's Hospital Of Philadelphia Compositions and methods for increasing the half-life of factor xa
MX2016009665A (es) 2014-01-24 2016-11-14 Pfizer Composiciones y metodos para el tratamiento de la hemorragia cerebral.

Also Published As

Publication number Publication date
CA2924981A1 (en) 2015-04-02
US10660946B2 (en) 2020-05-26
AR097732A1 (es) 2016-04-13
CA2924981C (en) 2020-03-31
CN112195169A (zh) 2021-01-08
MY173548A (en) 2020-02-04
PE20160877A1 (es) 2016-09-11
JP6429885B2 (ja) 2018-11-28
US20210106658A1 (en) 2021-04-15
RU2016108608A (ru) 2017-10-26
TWI631134B (zh) 2018-08-01
EP3049434A1 (en) 2016-08-03
US20170333535A1 (en) 2017-11-23
SA516370751B1 (ar) 2018-04-05
KR20160044034A (ko) 2016-04-22
TW201524996A (zh) 2015-07-01
MX2016003871A (es) 2016-08-04
AU2014326257A1 (en) 2016-03-10
IL279396A (en) 2021-01-31
HK1218760A1 (zh) 2017-03-10
KR101988705B1 (ko) 2019-06-12
SG11201601221XA (en) 2016-04-28
JP2016535071A (ja) 2016-11-10
IL244258A0 (en) 2016-04-21
CN105579468A (zh) 2016-05-11
AU2014326257B2 (en) 2017-08-10
US20150182604A1 (en) 2015-07-02
WO2015044836A1 (en) 2015-04-02
BR112016005899A8 (pt) 2018-02-06
US9757434B2 (en) 2017-09-12
RU2648144C2 (ru) 2018-03-22

Similar Documents

Publication Publication Date Title
CY1126072T1 (el) Περιοχες gla ως θεραπευτικοι παραγοντες
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CY1123865T1 (el) Τροποποιηση της εξειδικευσης δομημενου πολυπεπτιδιου
EA201491856A1 (ru) Терапевтическое применение белков фактора роста фибробластов 21
BR112015031073A2 (pt) inibidores bicíclicos de bromodomínio
BR112016012860A2 (pt) Compostos de biarila úteis no tratamento de doenças humanas em oncologia, neurologia e imunologia
GT201400057A (es) 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
EA201391175A1 (ru) Гетеродимерные иммуноглобулины
BR112015015898A2 (pt) composição farmacêutica de solução sólida
TR201903840T4 (tr) İnsan tamamlayıcı C5'e bağlanan polipeptitler.
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
CR20120508A (es) PROTEÍNA DE FUSIÓN ROBO1-Fc Y SU UTILIZACIÓN EN EL TRATAMIENTO DE TUMORES
BR112014021653A2 (pt) Formulação tópica, método para tratamento de feridas e método para fabricar uma formulação tópica
BR112016005899A2 (pt) composições compreendendo populações heterogêneas de proteínas de fator xa de coagulação recombinante humano
BR112015021483A2 (pt) arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer
BR112015026388A2 (pt) métodos e composições para cicatrização de feridas
EA201790349A1 (ru) Производные 6-алкинил-пиридина в качестве миметиков белка smac
BR112014032764A2 (pt) composição farmacêutica contendo fimasartana e hidroclorotiazida
BR112016008039A2 (pt) polipeptídeos do fator vii da coagulação
GEP201606514B (en) Apoptosis inhibitors and usage thereof
BR112015015182A2 (pt) polipeptídeos do fator vii de ação curta
CY1118967T1 (el) Φαρμακευτικες συνθεσεις υψηλης δοσης βιοτινης
BR112013024265A2 (pt) peptídeo cíclico, uso de peptídeos cíclicos, método para o tratamento de doenças, composição farmacêutica, composto para o diagnóstico de câncer, e, combinação farmacêutica
BRPI1006076B8 (pt) composições farmacêuticas
BR112015005268A2 (pt) seringa contendo uma composição, em particular farmacêutica, composta por imunoglobulinas, seu método de fabricação e respectivo uso

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2688 DE 12-07-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.